Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer's Disease - ADVANCE

Next Previous
Trial Profile

A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer's Disease - ADVANCE

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AD 04 Advantage Therapeutics (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors ADvantage Therapeutics

Most Recent Events

  • 20 Jun 2023 According to an ADvantage Therapeutics media release, company has announced that regulatory authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application (CTA) to conduct a clinical trial on its lead candidate, AD0 for the treatment of mild Alzheimers disease (AD) in each respective country.
  • 04 May 2023 Status changed from planning to recruiting.
  • 05 Apr 2023 According to Advantage media release, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the United Kingdom National Competent Authority has granted the company's lead compound AD04 for the treatment of Alzheimer's Disease under the Innovative Licensing and Access Pathway (ILAP).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top